<abbr id="skemw"><source id="skemw"></source></abbr>
<button id="skemw"><input id="skemw"></input></button>
<rt id="skemw"></rt>
<code id="skemw"><tr id="skemw"></tr></code>
<rt id="skemw"><acronym id="skemw"></acronym></rt>
<rt id="skemw"></rt>
您好!歡迎訪問廣州市超博科技有限公司的網站!
咨詢熱線: 18818844207
Bestatin (Synonyms:烏苯美司; Ubenimex)
Bestatin (Synonyms:烏苯美司; Ubenimex)
詳情說明 / Details
Bestatin (Synonyms:烏苯美司; Ubenimex)
目錄號 : KM12824 CAS No. : 58970-76-6 純度 : 98%
規格:

Bestatin (Ubenimex) 是 CD13 (Aminopeptidase N)/APN 和 leukotriene A4 hydrolase 抑制劑,常用于癌癥研究。

    生物活性

    Bestatin is a natural, broad-spectrum, and competitive CD13 (Aminopeptidase N)/APN and leukotriene A4 hydrolase inhibitor. Bestatin has anticancer effects.

    體外研究

    Bestatin enhances ATRA-induced differentiation and inhibits ATRA-driven phosphorylation of p38 MAPK in ATRA-sensitive APL NB4 cells. Bestatin can not reverse the differentiation block in ATRA-resistant APL MR2 cells. CD13 ligation with anti-CD13 antibody WM-15 results in phosphorylation of p38 MAPK, reduces the inhibition of Bestatin on the phosphorylation of p38 MAPK, and completely abolishes the enhancement of Bestatin on ATRA-inducing differentiation in NB4 cells. Bestatin (600 μM)-treated cells progress slower through the cell cycle due to decreased rate of cell growth and the frequency of cell division. Bestatin inhibits the frequency of mitosis and the inherent multinuclearity in D. discoideum, and is not cytotoxic to D. discoideum cells at 0-600 μM. Bestatin inhibits aminopeptidase activity in lysates of PsaA-GFP- and GFP-expressing cells by 69.39% and 39.93% of control, respectively.

    體內研究

    Bestatin (20 μM) significantly reduces CD13 expression in diabetic mice and results a significant inhibition of MMP-9 specific gelationolytic band densities compared to diabetic vehicle-treated mice. Bestatin treatment significantly inhibits the expression of VEGF and heparanase in diabetic mice. Intravitreal bestatin treatment significantly downregulates the expression of both HIF-1α and VEGF in diabetic mice retinas. Furthermore, the upregulated expression of heparanase in diabetic mice retinas is significantly inhibited by intravitreal bestatin treatment. Bestatin (10, 1, and 0.1mg/kg, i.p.) treatment before the antigen-potentiated humoral response to SRBC results in an increased number of splenocytes producing hemolytic anti-SRBC antibodies (PFC) and the 2-ME-resistant serum hemagglutinin titer (at a dose of 0.1 mg/kg). Bestatin (1 and 0.1 mg/kg) administered to mice five times on alternate days after cyclophosphamide injection does not change the suppressive effect of the drug regarding the number of PFC, and even causes the further decrease of the total anti-SRBC hemagglutinins at dose of 1 mg/kg on day 7 after antigen stimulation.

    分子式
    C16H24N2O4
    分子量
    308.37
    CAS號
    58970-76-6
    中文名稱
    烏苯美司
    運輸條件

    Room temperature in continental US; may vary elsewhere.

    儲存方式

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    溶解性數據
    In Vitro: 

    DMSO : 8.33 mg/mL (27.01 mM; Need ultrasonic)

    配制儲備液
    濃度溶劑體積質量 1 mg 5 mg 10 mg
    1 mM 3.2429 mL 16.2143 mL 32.4286 mL
    5 mM 0.6486 mL 3.2429 mL 6.4857 mL
    10 mM 0.3243 mL 1.6214 mL 3.2429 mL
    *

    請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產品失效。
    儲備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 儲存時,請在 6 個月內使用,-20°C 儲存時,請在 1 個月內使用。

    In Vivo:

    請根據您的實驗動物和給藥方式選擇適當的溶解方案。以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液,再依次添加助溶劑:

    ——為保證實驗結果的可靠性,澄清的儲備液可以根據儲存條件,適當保存;體內實驗的工作液,建議您現用現配,當天使用; 以下溶劑前顯示的百
    分比是指該溶劑在您配制終溶液中的體積占比;如在配制過程中出現沉淀、析出現象,可以通過加熱和/或超聲的方式助溶

    • 1.

      請依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 0.83 mg/mL (2.69 mM); Clear solution

      此方案可獲得 ≥ 0.83 mg/mL (2.69 mM,飽和度未知) 的澄清溶液。

      以 1 mL 工作液為例,取 100 μL 8.3 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中,混合均勻;向上述體系中加入50 μL Tween-80,混合均勻;然后繼續加入 450 μL生理鹽水定容至 1 mL。

    • 2.

      請依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 0.83 mg/mL (2.69 mM); Clear solution

      此方案可獲得 ≥ 0.83 mg/mL (2.69 mM,飽和度未知) 的澄清溶液。

      以 1 mL 工作液為例,取 100 μL 8.3 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中,混合均勻。

    • 3.

      請依序添加每種溶劑: 10% DMSO    90% corn oil

      Solubility: ≥ 0.83 mg/mL (2.69 mM); Clear solution

      此方案可獲得 ≥ 0.83 mg/mL (2.69 mM,飽和度未知) 的澄清溶液,此方案不適用于實驗周期在半個月以上的實驗。

      以 1 mL 工作液為例,取 100 μL 8.3 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中,混合均勻。

    臨床試驗
    科研文獻
    • ?J Med Chem. 2017 Mar 9;60(5):1817-1828.
    亚洲精品美女久久久久久久 | 国产精品一区二区三区久久| 久久永久免费人妻精品| 好好的曰com久久| 久久99亚洲网美利坚合众国| 国产美女亚洲精品久久久综合| 久久久久麻豆V国产精华液好用吗| 久久久久久久久久久久久久久| 精品国产91久久久久久久a| 亚洲中文字幕久久精品蜜桃| 久久婷婷五月综合色高清| 久久99精品久久久久久| 国产免费福利体检区久久| 肉色欧美久久久久久久蜜桃| 久久久久亚洲AV片无码下载蜜桃 | 久久久久人妻精品一区蜜桃| 精产国品久久一二三产区区别| 国产精品成人无码久久久| 国产精品一久久香蕉国产线看| 人妻少妇久久中文字幕一区二区| 国产综合久久久久| 久久五月精品中文字幕| 一本色道久久88亚洲综合| 久久精品免费一区二区喷潮| 久久久噜久噜久久gif动图| 人妻精品久久久久中文字幕69| 亚洲国产精品高清久久久| 99久久免费国产特黄| 一级做a爰片久久毛片毛片| 成人影院久久久久久影院| 久久WWW色情成人免费观看| 国产国产成人精品久久| 久久狠狠爱亚洲综合影院| 91久久精品国产91久久性色也| 久久久久久久伊人电影| 久久伊人免费视频| 久久精品中文字幕首页| 久久婷婷丁香五月综合五| 久久精品国产清白在天天线| 久久精品国产一区二区三区肥胖| 亚洲伊人久久精品影院|
  • <abbr id="a60w2"></abbr>
  • <strike id="a60w2"><input id="a60w2"></input></strike>